Tyler A. Longmire

1.5k total citations · 1 hit paper
14 papers, 922 citations indexed

About

Tyler A. Longmire is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Tyler A. Longmire has authored 14 papers receiving a total of 922 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in Tyler A. Longmire's work include Cancer Immunotherapy and Biomarkers (6 papers), Pluripotent Stem Cells Research (5 papers) and CAR-T cell therapy research (3 papers). Tyler A. Longmire is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Pluripotent Stem Cells Research (5 papers) and CAR-T cell therapy research (3 papers). Tyler A. Longmire collaborates with scholars based in United States, Switzerland and Singapore. Tyler A. Longmire's co-authors include Darrell N. Kotton, Constantina Christodoulou, Gustavo Mostoslavsky, Cesar Sommer, George J. Murphy, Steven S. Shen, Monica Gostissa, F W Alt, Andreia Gianotti Sommer and Laertis Ikonomou and has published in prestigious journals such as Journal of Clinical Investigation, Cancer Research and Clinical Cancer Research.

In The Last Decade

Tyler A. Longmire

14 papers receiving 917 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Tyler A. Longmire

Since Specialization

Citations

This map shows the geographic impact of Tyler A. Longmire's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tyler A. Longmire with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tyler A. Longmire more than expected).

Fields of papers citing papers by Tyler A. Longmire

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tyler A. Longmire. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tyler A. Longmire. The network helps show where Tyler A. Longmire may publish in the future.

Co-authorship network of co-authors of Tyler A. Longmire

This figure shows the co-authorship network connecting the top 25 collaborators of Tyler A. Longmire. A scholar is included among the top collaborators of Tyler A. Longmire based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tyler A. Longmire. Tyler A. Longmire is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity 2023 ·Science Advances ·(unknown), (unknown), (unknown), Michael J. Walsh, (unknown), Megan T. Hoffman, Michael Dougan, Tyler A. Longmire, Michael Wichroski, Stephanie K. Dougan	5
2	Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors breakdown → 2021 ·Clinical Cancer Research ·Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing	257
3	Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment 2021 ·Cancer Research ·Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp, Jinsheng Liang, Sema Kurtuluş, Gina M. Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, (unknown), Matthew D. Shirley, Yan Chen, Hao Wang, David A. Ruddy, Claire Fabre, Juliet Williams, Peter S. Hammerman, Jennifer Mataraza, Barbara Platzer, Ensar Halilovic	43
4	Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms 2021 ·Clinical Cancer Research ·Raajit K. Rampal, Maria Pinzon-Ortiz, Amritha Varshini Hanasoge Somasundara, Benjamin H. Durham, Richard P. Koche, Barbara Spitzer, (unknown), (unknown), Bing Li, (unknown), Andriy Derkach, (unknown), (unknown), Tyler A. Longmire, (unknown), (unknown), (unknown), Gary Vanasse, Zhu Cao, Ross L. Levine	14
5	439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity 2020 ·Regular and Young Investigator Award Abstracts ·Catherine Sabatos-Peyton, Tyler A. Longmire, (unknown), Nidhi Patel, Anne‐Sophie Wavreille, (unknown), Pushpa Jayaraman, Xiaomo Jiang, Stephanie Schwartz, Viviana Cremasco, Hongbo Lu, Shumei Qiu, Fiona A. Sharp, Mikael L. Rinne, Glenn Dranoff	7
6	Phase (Ph) II study of MBG453 + spartalizumab in patients (pts) with non-small cell lung cancer (NSCLC) and melanoma pretreated with anti–PD-1/L1 therapy 2019 ·Annals of Oncology ·Nicolas Mach, Giuseppe Curigliano, Armando Santoro, D.-W. Kim, David Tai, Stephen Hodi, Sofie Wilgenhof, Toshihiko Doi, Tyler A. Longmire, Haiying Sun, Alexandros Xyrafas, Sabine Gutzwiller, Lucio Manenti, (unknown)	22
7	Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies 2019 ·Cancer Research ·Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, Wai Meng David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, (unknown), P. Nikolopoulos, Luigi Manenti, Aung Naing	32
8	Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies 2019 ·Clinical Trials ·Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, Wai Meng David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, (unknown), P. Nikolopoulos, Luigi Manenti, Aung Naing	2
9	Abstract 2343: The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules 2016 ·Cancer Research ·Maria Pinzon-Ortiz, William D. Hastings, Tyler A. Longmire, Pamela Shaw, (unknown), Masato Murakami, Benjamin H. Lee, Glenn Dranoff, Kenzie D. MacIsaac, Z. Alexander Cao	2
10	Mouse ESC Differentiation to Nkx2.1+ Lung and Thyroid Progenitors 2012 ·BIO-PROTOCOL ·Tyler A. Longmire, Laertis Ikonomou, Darrell N. Kotton	5
11	Efficient Derivation of Purified Lung and Thyroid Progenitors from Embryonic Stem Cells 2012 ·Cell stem cell ·Tyler A. Longmire, Laertis Ikonomou, Finn Hawkins, Constantina Christodoulou, Yuxia Cao, Jenny Jean, Letty W. Kwok, Hongmei Mou, Jayaraj Rajagopal, Steven S. Shen, (unknown), Maria Paola Serra, Daniel J. Weiss, Michael D. Green, Hans-Willem Snoeck, María I. Ramirez, Darrell N. Kotton	294
12	Mouse ES and iPS cells can form similar definitive endoderm despite differences in imprinted genes 2011 ·Journal of Clinical Investigation ·Constantina Christodoulou, Tyler A. Longmire, Steven S. Shen, (unknown), Cesar Sommer, Paul Gadue, Avrum Spira, Valerie Gouon–Evans, George J. Murphy, Gustavo Mostoslavsky, Darrell N. Kotton	39
13	Reprogramming Fibroblasts into Induced Pluripotent Stem Cells Using a Single Lentiviral 'Stem Cell Cassette' Provides a Potential Source of Endoderm Precursors. 2009 ·Aba Somers, Tyler A. Longmire, Constantina Christodoulou, Darrell N. Kotton, Gustavo Mostoslavsky, G. J. Murphy	1
14	Excision of Reprogramming Transgenes Improves the Differentiation Potential of iPS Cells Generated with a Single Excisable Vector 2009 ·Stem Cells ·Cesar Sommer, Andreia Gianotti Sommer, Tyler A. Longmire, Constantina Christodoulou, (unknown), Monica Gostissa, F W Alt, George J. Murphy, Darrell N. Kotton, Gustavo Mostoslavsky	199

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact